{"organizations": [], "uuid": "ffba9070509640fafa7018a84a81494eeb26c931", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180418.html", "section_title": "Archive News &amp; Video for Wednesday, 18 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fibrocell-announces-review-of-stra/brief-fibrocell-announces-review-of-strategic-alternatives-idUSASC09W9X", "country": "US", "domain_rank": 408, "title": "BRIEF-Fibrocell Announces Review Of Strategic Alternatives", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.003, "site_type": "news", "published": "2018-04-18T20:20:00.000+03:00", "replies_count": 0, "uuid": "ffba9070509640fafa7018a84a81494eeb26c931"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fibrocell-announces-review-of-stra/brief-fibrocell-announces-review-of-strategic-alternatives-idUSASC09W9X", "ord_in_thread": 0, "title": "BRIEF-Fibrocell Announces Review Of Strategic Alternatives", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "fibrocell science inc", "sentiment": "negative"}, {"name": "genuity llc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 18 (Reuters) - Fibrocell Science Inc:\n* FIBROCELL ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES * FIBROCELL SCIENCE INC - HAS ENGAGED CANACCORD GENUITY LLC AS ITS STRATEGIC FINANCIAL ADVISOR TO ASSIST WITH THIS REVIEW PROCESS\n* FIBROCELL - POTENTIAL STRATEGIC ALTERNATIVES MAY INCLUDE SALE OF CO, BUSINESS COMBINATION, MERGER OR REVERSE MERGER WITH ANOTHER CO\n* FIBROCELL - POTENTIAL STRATEGIC ALTERNATIVES MAY INCLUDE STRATEGIC INVESTMENT INTO CO, SALE, LICENSE OR OTHER DISPOSITION OF CORPORATE ASSETS\n* FIBROCELL - POTENTIAL STRATEGIC ALTERNATIVES MAY INCLUDE CONTINUING WITH CURRENT BUSINESS PLAN\n* FIBROCELL SCIENCE INC - IN STRATEGIC REVIEW, BOARD IS CONSIDERING FIBROCELLâ€™S CLINICAL PROGRAMS FOR RARE SKIN DISEASES WITH UNMET NEEDS AMONG OTHERS\n* FIBROCELL SCIENCE - INTENDS TO CONTINUE ADVANCING PHASE 1/2 CLINICAL TRIAL OF FCX-007 AND PROVIDE A TRIAL UPDATE IN Q2 OF 2018\n* FIBROCELL - BELIEVES CASH AND CASH EQUIVALENTS AS OF MARCH 31 WILL BE SUFFICIENT TO FUND OPERATIONS INTO Q1 2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-18T20:20:00.000+03:00", "crawled": "2018-04-19T14:52:49.007+03:00", "highlightTitle": ""}